1. |
Chen W, Zheng R, Baade PD,et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
|
2. |
Vauthey JN, Dixon E. AHPBA/SSO/SSAT Consensus Conference on Resectable and Borderline Resectable Pancreatic Cancer: rationale and overview of the conference. Ann Surg Oncol, 2009, 16(7): 1725-1726.
|
3. |
Bliss LA, Witkowski ER, Yang CJ,et al. Outcomes in operative management of pancreatic cancer. J Surg Oncol, 2014, 110(5): 592-598.
|
4. |
Konstantinidis IT, Warshaw AL, Allen JN,et al. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a " true” R0 resection? Ann Surg, 2013, 257(4): 731-736.
|
5. |
Chicheportiche Y, Bourdon PR, Xu H,et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem, 1997, 272(51): 32401-32410.
|
6. |
Bossen C, Tardivel A, Bodmer JL,et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Bio Chem, 2006, 281(20): 13964-13971.
|
7. |
Bergers G. Tumorigenesis and the angiogenic switch. Nat Rev Cancer, 2003, 3(6): 401-410.
|
8. |
Tonini T, Rossi F, Claudio PP. Molecular basis of angiogenesis and cancer. Oncogene, 2003, 22(42): 6549-6556.
|
9. |
Cao Y. Antiangiogenic cancer therapy. Semin Cancer Biol, 2004, 14(2): 139-145.
|
10. |
Sun SC. Non-canonical NF-κB signaling pathway. Cell Res, 2011, 21(1): 71-85.
|
11. |
Hoesel B, Schmid JA. The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer, 2013, 12(1): 86.
|
12. |
Kwon OH, Kim JH, Kim SY,et al. TWEAK/Fn14 signaling mediates gastric cancer cell resistance to 5-fluorouracil via NF-κB activation. Int J Oncol, 2014, 44(2): 583-590.
|
13. |
Chen HN, Wang DJ, Ren MY,et al.TWEAK/Fn14 promotes the proliferation and collagen synthesis of rat cardiac fibroblasts via the NF-кB pathway. Mol Biol Rep, 2012, 39(8): 8231-8241.
|
14. |
Li X, Li Y, Wang B,et al. Delivery of the co-expression plasmid pEndo-Si-Stat3 by attenuated Salmonella serovar typhimurium for prostate cancer treatment. J Cancer Res Clin Oncol, 2013: 139(6): 971-980.
|
15. |
Kuribayashi K, Mayes PA, El-Deiry WS. What are caspases 3 and 7 doing upstream of the mitochondria? Cancer Biol Ther, 2006, 5(7): 763-765.
|
16. |
Wang D, Fung JN, Tuo Y,et al. TWEAK/Fn14 promotes apoptosis of human endometrial cancer cells via caspase pathway. Cancer Lett, 2010, 294(1): 91-100.
|
17. |
Pettersen I, Baryawno N, Abel F,et al. Expression of TWEAK/Fn14 in neuroblastoma: implications in tumorigenesis. Int J Oncol, 2013, 42(4): 1239-1248.
|
18. |
Kawakita T, Yamanaka Y, Yamaguchi Y,et al. Functional expression of TWEAK in human hepatocellular carcinoma: possible implication in cell proliferation and tumor angiogenesis. Biochem Biophys Res Commun, 2004, 318(3): 726-733.
|
19. |
Zhao H, Langerød A, Y Ji,et al. Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell, 2004, 15(6): 2523-2536.
|
20. |
Gu L, Dai L, Cao C,et al. Functional expression of TWEAK and the receptor Fn14 in human malignant ovarian tumors: possible implication for ovarian tumor intervention. PLoS One, 2013, 8(3): e57436.
|
21. |
Zou H, Wang D, Gan X,et al. Low TWEAK expression is correlated to the progression of squamous cervical carcinoma. Gynecol Oncol, 2011, 123(1): 123-128.
|
22. |
Burkly LC, Zheng TS. TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Immunol Rev, 2011, 244(1): 99-114.
|
23. |
Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov, 2008, 7(5): 11-25.
|
24. |
Burkly LC, Dohi T. The TWEAK/Fn14 pathway in tissue remodeling: for better or for worse. Adv Exp Med Biol, 2011, 691: 305-322.
|
25. |
Dohi T, LC Burkly. TWEAK/Fn14 pathway as an aggravating and perpetuating factor in inflammatory diseases: focus on inflammatory bowel diseases. J Leukoc Biol, 2012, 92(2): 265-279.
|